Exact Mass: 426.2492
Exact Mass Matches: 426.2492
Found 500 metabolites which its exact mass value is equals to given mass value 426.2492,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Oxatomide
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AE - Piperazine derivatives D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents Oxatomide is a first-generation piperazine H1-antihistamine. D018926 - Anti-Allergic Agents Oxatomide is a potent and orally active dual H1-histamine receptor and P2X7 receptor antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in human P2X7 receptors (IC50 of 0.95 μM). Oxatomide inhibits ATP-induced Ca2+ influx with an IC50 value of 0.43 μM and also inhibits serotonin[1][2].
Prostaglandin PGE2 1-glyceryl ester
2-Arachidonoyl glycerol (2-AG) has been isolated from porcine brain,1 and has been characterized as the natural endocannabinoid ligand for the CB1 receptor.2 Incubation of 2-AG with COX-2 and specific prostaglandin H2 (PGH2) isomerases in cell cultures and isolated enzyme preparations results in prostaglandin glycerol ester formation.3 The biosynthesis of PGH, PGD, PGE, PGF, and TXA-2-glyceryl ester compounds have all been documented. The 2-glyceryl ester moiety equilibrates rapidly (within minutes) with the more stable 1-glyceryl ester, producing a 10:90 2:1-glyceryl ester mixture in typical aqueous media. While the stability and metabolism of these prostaglandin products has been investigated,4 little is known about their intrinsic biological activity. [HMDB] 2-Arachidonoyl glycerol (2-AG) has been isolated from porcine brain,1 and has been characterized as the natural endocannabinoid ligand for the CB1 receptor.2 Incubation of 2-AG with COX-2 and specific prostaglandin H2 (PGH2) isomerases in cell cultures and isolated enzyme preparations results in prostaglandin glycerol ester formation.3 The biosynthesis of PGH, PGD, PGE, PGF, and TXA-2-glyceryl ester compounds have all been documented. The 2-glyceryl ester moiety equilibrates rapidly (within minutes) with the more stable 1-glyceryl ester, producing a 10:90 2:1-glyceryl ester mixture in typical aqueous media. While the stability and metabolism of these prostaglandin products has been investigated,4 little is known about their intrinsic biological activity.
Cinnzeylanine
Constituent of Cinnamomum zeylanicum (cinnamon) and Cinnamomum cassia (Chinese cinnamon). Cinnzeylanine is found in chinese cinnamon, ceylon cinnamon, and herbs and spices. Cinnzeylanine is found in ceylan cinnamon. Cinnzeylanine is a constituent of Cinnamomum zeylanicum (cinnamon) and Cinnamomum cassia (Chinese cinnamon)
Prostaglandin D2-1-glyceryl ester
2-Arachidonoyl glycerol (2-AG) has been isolated from porcine brain, and has been characterized as the natural endocannabinoid ligand for the CB1 receptor.1,2 Incubation of 2-AG with cyclooxygenase-2 (COX-2) and specific prostaglandin H2 (PGH2) isomerases in cell cultures and isolated enzyme preparations results in prostaglandin glycerol ester formation.3 The biosynthesis of PGH, PGD, PGE, PGF, and TXA-2-glyceryl ester compounds have all been documented. In RAW 264.7 cells, PGD2-2-glyceryl ester is the main COX metabolite.3 The 2-glyceryl ester moiety equilibrates rapidly (within minutes) with the more stable 1-glyceryl ester, producing a 10:90 mixture of the 1- and 2-glyceryl esters in typical aqueous media. While the stability and metabolism of these PG products have been investigated, little is known about their intrinsic biological activity. [HMDB] 2-Arachidonoyl glycerol (2-AG) has been isolated from porcine brain, and has been characterized as the natural endocannabinoid ligand for the CB1 receptor.1,2 Incubation of 2-AG with cyclooxygenase-2 (COX-2) and specific prostaglandin H2 (PGH2) isomerases in cell cultures and isolated enzyme preparations results in prostaglandin glycerol ester formation.3 The biosynthesis of PGH, PGD, PGE, PGF, and TXA-2-glyceryl ester compounds have all been documented. In RAW 264.7 cells, PGD2-2-glyceryl ester is the main COX metabolite.3 The 2-glyceryl ester moiety equilibrates rapidly (within minutes) with the more stable 1-glyceryl ester, producing a 10:90 mixture of the 1- and 2-glyceryl esters in typical aqueous media. While the stability and metabolism of these PG products have been investigated, little is known about their intrinsic biological activity.
Prostaglandin PGE2 glyceryl ester
GE2 glycerol ester is a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. 2-Arachidonoyl glycerol (2-AG) has been isolated from porcine brain,1 and has been characterized as the natural endocannabinoid ligand for the CB1 receptor.2 Incubation of 2-AG with COX-2 and specific prostaglandin H2 (PGH2) isomerases in cell cultures and isolated enzyme preparations results in prostaglandin glycerol ester formation.3 The biosynthesis of PGH, PGD, PGE, PGF, and TXA-2-glyceryl ester compounds have all been documented. The 2-glyceryl ester moiety equilibrates rapidly (within minutes) with the more stable 1-glyceryl ester, producing a 10:90 2:1-glyceryl ester mixture in typical aqueous media. While the stability and metabolism of these prostaglandin products has been investigated,4 little is known about their intrinsic biological activity. Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. GE2 glycerol ester is a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons
Darifenacin
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists Darifenacin (Enablex, Novartis) is a medication used to treat urinary incontinence. C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D000089162 - Genitourinary Agents > D064804 - Urological Agents Darifenacin(UK88525) is a selective M3 muscarinic receptor antagonist with pKi of 8.9. IC50 value: 8.9 (pKi) [1] Target: M3 receptor in vitro: Darifenacin exerts non-parallel rightward displacement of the agonist curve and also significant depression of the maximum response (+)-cis-Dioxolane produced concentration-dependent contraction of the isolated bladder of rat [1]. Darifenacin produces a concentration dependent increase in R123 (P-gp probe) accumulation in MDCK cells. Darifenacin stimulates ATPase activity in P-gp membrane in a clear concentration dependent response manner with an estimated ED50 value of 1.6 μM. Darifenacin (100 nM) shows a significantly greater permeability for darifenacin in the basolateral to apical direction resulting in an efflux ratio in BBMEC monolayers of approximately 2.6 [2]. in vivo: Darifenacin produces dose-dependent inhibition of amplitude of volume-induced bladder contractions(VIBCAMP), producing 35\% inhibition at dose of 283.3 nmol/kg and maximal inhibition of approximately 50–55\% [1]. Darifenacin (0.1 mg/kg i.v.) reduces bladder afferent activity in both Aδ and C fibers in female Sprague-Dawley rats, the decrease in afferent spikes in C fibers may be more pronounced than that in Aδ fibers [3].
Prostaglandin H2 2-glyceryl Ester
Prostaglandin H2 2-glyceryl Ester is also known as 2-Glyceryl-prostaglandin H2. Prostaglandin H2 2-glyceryl Ester is considered to be practically insoluble (in water) and relatively neutral. Prostaglandin H2 2-glyceryl Ester is an eicosanoid lipid molecule
(23R)-1alpha-Hydroxy-25,27-didehydrovitamin D3 26,23-lactone
Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-4-hydroxy-3-methoxy-alpha-(1-methylethyl)-
(2s)-7-Amino-2-{[(R)-Hydroxy{(1r)-2-Methyl-1-[(3-Phenylpropanoyl)amino]propyl}phosphoryl]methyl}heptanoic Acid
MG(PGE2/0:0/0:0)
MG(PGE2/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(PGD2/0:0/0:0)
MG(PGD2/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/0:0/0:0)
MG(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/PGE2/0:0)
MG(0:0/PGE2/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/PGD2/0:0)
MG(0:0/PGD2/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/0:0)
MG(0:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
Cichorioside N
Cichorioside n is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Cichorioside n can be found in endive, which makes cichorioside n a potential biomarker for the consumption of this food product.
(rel-5S,6R,8R,9R,10S,13R,14S,15R,16S)-6-acetoxy-9,16;15,16-diepoxy-13,14-dihydroxy-15-methoxylabdane|viteagnusin G
2-[(2E,6Z,10E)-5-oxo-13-hydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]-6-methylhydroquinone
3-O-acetyl-4,5-O-di-(3methylvaleryl)-shikimic acid methyl ester|3-O-acetyl-4,5-O-di-<3methylvaleryl>-shikimic acid methyl ester
(1E,4S,5E,7R)-2-O-acetyl-7-O-beta-D-glucopyranosylgermacra-1(10),5-diene
(4S,7R)-7-[(1E,3E,5E,7E)-8-[(2S,5R,6S)-5,6-dihydro-5-hydroxy-3,5,6-trimethyl-2H-pyran-2-yl]nona-1,3,5,7-tetraen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione|wortmannilactone F
(5Z,8Z,11Z,13E,17Z)-2-eicosa-15(S)-hydroxy-5,8,11,13,17-pentaenoylphloroglucinol
7alpha,21-dihydroxy-3-oxo-24,25,26,27-tetranorapotirucall-1,14,20(22)-trien-21,23-olide
(1R,2S)-1-{[(1S,4aR,5R,8aS)-decahydro-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthalen-1-yl]methoxy}propane-1,2,3-tricarboxylic acid 2-methyl ester|cryptoporic acid N
6beta-benzoyl-12-methyl-9(12)a,9(12)b-dihomopodocarpane-3beta,13beta-diol|dulcinodiol
5-{(E)-2-[2-(1H-indol-5-yl)-1,4-bis(methoxymethyl)cyclohex-3-en-1-yl]ethenyl}-1H-indole|caulindole E
(1E,4S,5E,7R)-6O-acetyl-7-O-beta-D-glucopyranosylgermacra-1(10),5-diene
2,3-epoxy-5beta,6beta,9,10alpha,16alpha-pentahydroxy-7alpha-acetoxygrayanane|craiobiotoxin IV
16beta-acetyloxy-14-hydroxy-bufa-5,20,22-trienolide
(5beta,9alpha,10alpha)-7-O-(3alpha-methoxy-8(12)-drimen-11-yl)-scopoletin|driportlandin
8beta-hydroxy-15-malonyloxy-ent-labdan-18-oic acid
3,4-dihydroxy-5-(E,E,E-3,7,11,15-tetramethyl-hexadeca-2,6,10,14-tetraenyl)benzoic acid
(25r)-4-spirosten-3,12-dione
(25R)-Spirost-4-ene-3,12-dione is a natural product found in Tribulus terrestris and Persicaria chinensis with data available.
GarcinoicAcid
(2e,6e,10e)-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydrochromen-2-yl]-2,6,10-trimethyltrideca-2,6,10-trienoic acid is a tocotrienol. GarcinoicAcid is a natural product found in Garcinia kola with data available.
C27H38O4_(2E,6E,10E)-13-[(2R)-6-Hydroxy-2,8-dimethyl-3,4-dihydro-2H-chromen-2-yl]-2,6,10-trimethyl-2,6,10-tridecatrienoic acid
(2E,6E,10E)-13-[(2R)-6-hydroxy-2,8-dimethyl-3,4-dihydrochromen-2-yl]-2,6,10-trimethyltrideca-2,6,10-trienoic acid
(2E,6E,10E)-13-[(2R)-6-hydroxy-2,8-dimethyl-3,4-dihydrochromen-2-yl]-2,6,10-trimethyltrideca-2,6,10-trienoic acid_major
(2E,6E,10E)-13-[(2R)-6-hydroxy-2,8-dimethyl-3,4-dihydrochromen-2-yl]-2,6,10-trimethyltrideca-2,6,10-trienoic acid_3.4\\%
Ala His Ile Ser
Ala His Leu Ser
Ala His Ser Ile
Ala His Ser Leu
Ala His Thr Val
Ala His Val Thr
Ala Ile His Ser
Ala Ile Ser His
Ala Leu His Ser
Ala Leu Ser His
Ala Ser His Ile
Ala Ser His Leu
Ala Ser Ile His
Ala Ser Leu His
Ala Thr His Val
Ala Thr Val His
Ala Val His Thr
Ala Val Thr His
Gly His Ile Thr
Gly His Leu Thr
Gly His Thr Ile
Gly His Thr Leu
Gly Ile His Thr
Gly Ile Thr His
Gly Leu His Thr
Gly Leu Thr His
Gly Thr His Ile
Gly Thr His Leu
Gly Thr Ile His
Gly Thr Leu His
His Ala Ile Ser
His Ala Leu Ser
His Ala Ser Ile
His Ala Ser Leu
His Ala Thr Val
His Ala Val Thr
His Gly Ile Thr
His Gly Leu Thr
His Gly Thr Ile
His Gly Thr Leu
His Ile Ala Ser
His Ile Gly Thr
His Ile Ser Ala
His Ile Thr Gly
His Leu Ala Ser
His Leu Gly Thr
His Leu Ser Ala
His Leu Thr Gly
His Ser Ala Ile
His Ser Ala Leu
His Ser Ile Ala
His Ser Leu Ala
His Thr Ala Val
His Thr Gly Ile
His Thr Gly Leu
His Thr Ile Gly
His Thr Leu Gly
His Thr Val Ala
His Val Ala Thr
His Val Thr Ala
Ile Ala His Ser
Ile Ala Ser His
Ile Gly His Thr
Ile Gly Thr His
Ile His Ala Ser
Ile His Gly Thr
Ile His Ser Ala
Ile His Thr Gly
Ile Pro Pro Thr
Ile Pro Thr Pro
Ile Ser Ala His
Ile Ser His Ala
Ile Thr Gly His
Ile Thr His Gly
Ile Thr Pro Pro
Leu Ala His Ser
Leu Ala Ser His
Leu Gly His Thr
Leu Gly Thr His
Leu His Ala Ser
Leu His Gly Thr
Leu His Ser Ala
Leu His Thr Gly
Leu Pro Pro Thr
Leu Pro Thr Pro
Leu Ser Ala His
Leu Ser His Ala
Leu Thr Gly His
Leu Thr His Gly
Leu Thr Pro Pro
Pro Ile Pro Thr
Pro Ile Thr Pro
Pro Leu Pro Thr
Pro Leu Thr Pro
Pro Pro Ile Thr
Pro Pro Leu Thr
Pro Pro Thr Ile
Pro Pro Thr Leu
Pro Thr Ile Pro
Pro Thr Leu Pro
Pro Thr Pro Ile
Pro Thr Pro Leu
Ser Ala His Ile
Ser Ala His Leu
Ser Ala Ile His
Ser Ala Leu His
Ser His Ala Ile
Ser His Ala Leu
Ser His Ile Ala
Ser His Leu Ala
Ser Ile Ala His
Ser Ile His Ala
Ser Leu Ala His
Ser Leu His Ala
Thr Ala His Val
Thr Ala Val His
Thr Gly His Ile
Thr Gly His Leu
Thr Gly Ile His
Thr Gly Leu His
Thr His Ala Val
Thr His Gly Ile
Thr His Gly Leu
Thr His Ile Gly
Thr His Leu Gly
Thr His Val Ala
Thr Ile Gly His
Thr Ile His Gly
Thr Ile Pro Pro
Thr Leu Gly His
Thr Leu His Gly
Thr Leu Pro Pro
Thr Pro Ile Pro
Thr Pro Leu Pro
Thr Pro Pro Ile
Thr Pro Pro Leu
Thr Val Ala His
Thr Val His Ala
Val Ala His Thr
Val Ala Thr His
Val His Ala Thr
Val His Thr Ala
Val Thr Ala His
Val Thr His Ala
(23S)-1α-hydroxy-25,27-didehydrovitamin D3 26,23-lactone
(23R)-1α-hydroxy-25,27-didehydrovitamin D3 26,23-lactone
1-PGE(,2)-g
PGD2-1-Glyceryl ester
Darifenacin
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D000089162 - Genitourinary Agents > D064804 - Urological Agents Darifenacin(UK88525) is a selective M3 muscarinic receptor antagonist with pKi of 8.9. IC50 value: 8.9 (pKi) [1] Target: M3 receptor in vitro: Darifenacin exerts non-parallel rightward displacement of the agonist curve and also significant depression of the maximum response (+)-cis-Dioxolane produced concentration-dependent contraction of the isolated bladder of rat [1]. Darifenacin produces a concentration dependent increase in R123 (P-gp probe) accumulation in MDCK cells. Darifenacin stimulates ATPase activity in P-gp membrane in a clear concentration dependent response manner with an estimated ED50 value of 1.6 μM. Darifenacin (100 nM) shows a significantly greater permeability for darifenacin in the basolateral to apical direction resulting in an efflux ratio in BBMEC monolayers of approximately 2.6 [2]. in vivo: Darifenacin produces dose-dependent inhibition of amplitude of volume-induced bladder contractions(VIBCAMP), producing 35\% inhibition at dose of 283.3 nmol/kg and maximal inhibition of approximately 50–55\% [1]. Darifenacin (0.1 mg/kg i.v.) reduces bladder afferent activity in both Aδ and C fibers in female Sprague-Dawley rats, the decrease in afferent spikes in C fibers may be more pronounced than that in Aδ fibers [3].
Cinnzeylanine
(23S)-1alpha-hydroxy-25,27-didehydrovitamin D3 26,23-lactone
D018977 - Micronutrients > D014815 - Vitamins > D004100 - Dihydroxycholecalciferols D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols
(23R)-1alpha-hydroxy-25,27-didehydrovitamin D3 26,23-lactone
D018977 - Micronutrients > D014815 - Vitamins > D004100 - Dihydroxycholecalciferols D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols
2-eicosa-15S-hydroxy-5Z,8Z,11Z,13E,17Z-pentaenoylphloroglucinol
2-benzofuran-1,3-dione,2-[2-(2-hydroxyethoxy)ethoxy]ethanol,2,2,4-trimethylhexane
10,15-Dihydro-5,5,10,10,15,15-hexamethyl-5H-tribenzo[a,f,k]trindene
Nickel,bis(2,2,6,6-tetramethyl-3,5-heptanedionato-kO3,kO5)-, (SP-4-1)-
4(or 5)-(di-1H-indol-1-ylmethyl)-α,α-dimethylcyclohexenebutan-1-ol
d,l-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol hcl
1,3-diisocyanato-2-methylbenzene,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,hexane-1,6-diol
n-3-(triethoxysilylpropyl)-n-3-(trimethoxysilyl-propyl)urea
oxatomide
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AE - Piperazine derivatives D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents D018926 - Anti-Allergic Agents Oxatomide is a potent and orally active dual H1-histamine receptor and P2X7 receptor antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in human P2X7 receptors (IC50 of 0.95 μM). Oxatomide inhibits ATP-induced Ca2+ influx with an IC50 value of 0.43 μM and also inhibits serotonin[1][2].
prostaglandin E2 1-glyceryl ester
A 1-monoglyceride resulting from the condensation of the carboxy group of prostaglandin E2 with the 1-hydroxy group of glycerol.
(3S,3aR,4S,6S,7R,7aR)-6-ethenyl-4-hydroxy-3,6-dimethyl-7-[(E)-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyprop-1-en-2-yl]-3,3a,4,5,7,7a-hexahydro-1H-inden-2-one
5-[2-[(4E)-4-[(2Z)-2-(3,5-dihydroxy-2-methylidenecyclohexylidene)ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]propyl]-3-methylideneoxolan-2-one
N-[3-(diethylamino)propyl]-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide
1-[[4-Anilino-6-(1-piperidinyl)-1,3,5-triazin-2-yl]amino]-3-cyclohexylthiourea
N-[2-(cyclohexylamino)-2-oxoethyl]-N-(5-methyl-3-isoxazolyl)-N-phenylpentanediamide
(3aS,5S,9aS)-2-[(2-methylphenyl)methyl]-5-(1-methyl-3-phenyl-4-pyrazolyl)-3a,4,5,7,8,9-hexahydro-3H-pyrrolo[3,4-h]pyrrolizin-1-one
(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3R)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
3-methyl-2-[[2-(methylamino)-1-oxopropyl]amino]-N-[3-methyl-1-(1-naphthalenylamino)-1-oxobutan-2-yl]butanamide
3-[3-[4-[Hydroxy(diphenyl)methyl]-1-piperidinyl]propoxy]benzonitrile
(1S,5R)-3-[(3,5-dimethoxyphenyl)methyl]-7-[4-[(E)-2-phenylethenyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
(2R,3R)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
1-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
(2S,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3R)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
(2R,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
1-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
(2R,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
1,3-dihydroxypropan-2-yl (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
1-(4-Azidobenzyl)-4-[2-(diphenylmethoxy)ethyl]piperidine
2-[hydroxy-[(2R)-2-hydroxy-3-undecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2,3-dihydroxypropyl [2-hydroxy-3-[(Z)-tridec-9-enoxy]propyl] hydrogen phosphate
2-[2,3-Di(pentanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-(2-hydroxy-3-undecanoyloxypropoxy)phosphoryl]oxyethyl-trimethylazanium
2-[(3-Acetyloxy-2-octanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[(3-Butanoyloxy-2-hexanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[(2-Heptanoyloxy-3-propanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-(3-octoxy-2-propanoyloxypropoxy)phosphoryl]oxyethyl-trimethylazanium
2-[(2-Acetyloxy-3-nonoxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
prostaglandin I2 2-glyceryl ester
A 2-monoglyceride obtained by formal condensation of the carboxy group of prostaglandin I2 with the 2-hydroxy group of glycerol.
Prostaglandin H2 2-glyceryl Ester
A 2-monoglyceride obtained by formal condensation of the carboxy group of prostaglandin H2 with the 2-hydroxy group of glycerol.
prostaglandin D2 1-glyceryl ester
A 1-monoglyceride resulting from the condensation of the carboxy group of prostaglandin D2 with the 1-hydroxy group of glycerol.
prostaglandin D2 2-glyceryl ester
A 2-monoglyceride resulting from the condensation of the carboxy group of prostaglandin D2 with the 2-hydroxy group of glycerol.
prostaglandin E2 2-glyceryl ester
A 2-monoglyceride obtained by formal condensation of the carboxy group of prostaglandin E2 with the 2-hydroxy group of glycerol.
(±)-Darifenacin
(±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist[1].
SB269652
SB269652 is the first drug-like allosteric modulator of the dopamine D2 receptor (D2R); a new chemical probe that can differentiate D2R monomers from dimers or oligomers depending on the observed pharmacology. IC50 value: 0.2/0.5 nM [1] Target: D3 receptor antagonist SB269,652 potently (low nanomolar range) abolished specific binding of [(3)H]nemanopride and [(3)H]spiperone to Chinese hamster ovary-transfected D(3) receptors when radioligands were used at 0.2 and 0.5 nM, respectively. However, even at high concentrations (5 μM), SB269,652 only submaximally inhibited the specific binding of these radioligands when they were employed at 10-fold higher concentrations. By analogy, although SB269,652 potently blocked D(3) receptor-mediated activation of Gα(i3) and phosphorylation of extracellular-signal-regulated kinase (ERK)1/2, when concentrations of dopamine were increased by 10-fold, from 1 μM to 10 μM, SB269,652 only submaximally inhibited dopamine-induced stimulation of Gα(i3) [1].
10-(6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl)-3,7-dimethyl-2-(2-methylprop-1-en-1-yl)deca-3,7-dienoic acid
(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-{[(1r,2e,4s,7e)-4-isopropyl-1,7-dimethylcyclodeca-2,7-dien-1-yl]oxy}oxan-3-yl acetate
(1s,2s,6r,7r,8r,10r,12s,13s)-12-hydroxy-6-(hydroxymethyl)-2,6,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0²,⁷]hexadecan-8-yl benzoate
(1s,2r,3r,4r,7s,8z,12s,13s,14s,17s)-3,12,14,17-tetrahydroxy-4,9,13,17-tetramethyl-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadec-8-en-2-yl acetate
(2e,10e)-1-(2,5-dihydroxy-3-methylphenyl)-16-hydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-5-one
2-[(2z,6e,9r,10e)-8,9-dihydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-6-methylcyclohexa-2,5-diene-1,4-dione
(1s,2r,5s,6s,7s,9r)-5-(acetyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl (2e)-3-phenylprop-2-enoate
(7r)-7-[(1e,3e,5e,7e)-8-[(2s,3r,6s)-3-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl]nona-1,3,5,7-tetraen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
7-[8-(3-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl)nona-1,3,5,7-tetraen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
2-[(2e,6e,8r,9r,10e)-8,9-dihydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-6-methylcyclohexa-2,5-diene-1,4-dione
1,4,4,10,10-pentamethyl-11-(3-methylbut-2-en-1-yl)-9-(2-methylbutanoyl)-3-oxatricyclo[7.3.1.0²,⁷]trideca-2(7),5-diene-8,13-dione
5,5'-diisopropyl-3,3',8,8'-tetramethyl-[2,2'-binaphthalene]-1,1'-diol
1-(6-hydroxy-2,8-dimethylchromen-2-yl)-4,8,12-trimethyltrideca-3,7,11-triene-5,6-diol
2-[(2e,6e,10e)-15-hydroxy-3,7,11,15-tetramethyl-14-oxohexadeca-2,6,10-trien-1-yl]-6-methylcyclohexa-2,5-diene-1,4-dione
(2s,2'r,3s,3ar,4'r,4'as,6r,7ar,8'as)-3,3a-dihydroxy-2-methoxy-2',5',5',8'a-tetramethyl-decahydro-2h,2'h-spiro[furo[2,3-b]pyran-6,1'-naphthalen]-4'-yl acetate
1-(2,5-dihydroxy-3-methylphenyl)-13-hydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-5-one
(1s,1's,2's,5's,9's,10'r,13'r,14's)-5',10',14'-trimethyl-6',16'-dioxaspiro[cyclohexane-1,7'-pentacyclo[12.3.3.0¹,¹³.0²,¹⁰.0⁵,⁹]icosan]-3-ene-2,5,15'-trione
(1r,2s,3s,5s,6s,8s,9s,10s,11r,15s,16r)-3,9,10,15-tetrahydroxy-16-methoxy-6-(methoxymethyl)-12,12-dimethyl-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-7-one
(2z,6e,10e)-12-(2,5-dihydroxy-3-methylphenyl)-6,10-dimethyl-2-(4-methylpent-3-en-1-yl)dodeca-2,6,10-trienoic acid
(2z,6e,10e,14e)-16-(2,5-dihydroxy-3-methylphenyl)-2,6,10,14-tetramethylhexadeca-2,6,10,14-tetraenoic acid
8-[2-(furan-3-yl)-2-hydroxyethyl]-3,4,5-trihydroxy-4-(hydroxymethyl)-4a,7,8-trimethyl-hexahydro-1h-naphthalen-1-yl acetate
(3e,5r,6r,7e)-1-[(2r)-6-hydroxy-2,8-dimethylchromen-2-yl]-4,8,12-trimethyltrideca-3,7,11-triene-5,6-diol
5-[(6e)-14-(3-hydroxy-5-methoxyphenyl)tetradec-6-en-1-yl]benzene-1,3-diol
(4r,6e)-4-hydroxy-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-2,6,10-trien-5-one
7-[8-(5-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl)nona-1,3,5,7-tetraen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
(2e,6z,10e,13r)-1-(2,5-dihydroxy-3-methylphenyl)-13-hydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-5-one
4-hydroxy-13-(6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl)-2,6,10-trimethyltrideca-2,6,10-trien-5-one
[(1r,2s,5r,6s,7s,8r,9s,10s,11r,18r)-6,7,9,10,18-pentahydroxy-12,12-dimethyl-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-6-yl]methyl acetate
3-{[(1r,2r,4br,7r,8as,10as)-7-hydroxy-1,2,4b,8,8-pentamethyl-3,5,6,7,8a,9,10,10a-octahydro-2h-phenanthren-1-yl]methyl}-4-hydroxybenzoic acid
2-{2-[(1-hydroxyethylidene)amino]-n,3-dimethylbutanamido}-n-[(1z)-2-(1h-indol-3-yl)ethenyl]-4-methylpentanimidic acid
[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-{[(1r,2e,4s,7e)-4-isopropyl-1,7-dimethylcyclodeca-2,7-dien-1-yl]oxy}oxan-2-yl]methyl acetate
[(1s,3r,5r,7ar)-7-(hydroxymethyl)-3,5-dimethoxy-1-[(3-methylbutanoyl)oxy]-1h,3h,5h,7ah-cyclopenta[c]pyran-4-yl]methyl 3-methylbutanoate
(2s,2's,3r,3as,4's,4'ar,6s,7ar,8'ar)-3,3a-dihydroxy-2-methoxy-2',5',5',8'a-tetramethyl-decahydro-2h,2'h-spiro[furo[2,3-b]pyran-6,1'-naphthalen]-4'-yl acetate
25r-spirost-4-en-3,12-dione
{"Ingredient_id": "HBIN004751","Ingredient_name": "25r-spirost-4-en-3,12-dione","Alias": "NA","Ingredient_formula": "C27H38O4","Ingredient_Smile": "CC1CCC2(C(C3C(O2)CC4C3(C(=O)CC5C4CCC6=CC(=O)CCC56C)C)C)OC1","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "20202","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
asebotoxin i
{"Ingredient_id": "HBIN017046","Ingredient_name": "asebotoxin i","Alias": "NA","Ingredient_formula": "C23H38O7","Ingredient_Smile": "CCC(=O)OC1C2CCC3C1(CC(C4(C(C3(C)O)CC(C4(C)C)O)O)O)CC2(C)O","Ingredient_weight": "426.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1848","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "135929163","DrugBank_id": "NA"}
